Personalized Uterine Fibroid Treatment Platform

A next-generation platform for treating uterine fibroids, integrating real-time monitoring, personalized medicine, and advanced tissue breakdown techniques to provide more effective and minimally invasive treatments.

The original patent's treatment method using purified collagenase has limitations in terms of efficacy, dosage, and delivery. The new inventive concept addresses these limitations by incorporating cutting-edge technologies such as wearable devices, genetic profiling, high-frequency ultrasound, and machine learning algorithms to provide a more comprehensive and targeted approach to uterine fibroid treatment.

The platform consists of a wearable device that administers a customized dose of collagenase to the fibroid tissue based on real-time ultrasound monitoring of fibroid size and shape. Additionally, a patient's genetic profile is analyzed to determine the optimal dosage and formulation of collagenase for maximum efficacy. The platform also includes a composition comprising a combination of collagenase and a fibroblast growth factor inhibitor to enhance the degradation of collagen and reduce fibroid growth. Furthermore, a minimally invasive probe delivers a high-frequency ultrasound pulse to the fibroid tissue, followed by administration of collagenase to enhance tissue breakdown. A computer-implemented system predicts the likelihood of uterine fibroid recurrence, based on machine learning algorithms that analyze a patient's medical history, genetic profile, and fibroid characteristics.

The new claims introduce a paradigm shift in uterine fibroid treatment by integrating wearable devices, genetic profiling, high-frequency ultrasound, and machine learning algorithms, which are not present in the original patent. The inventive concept's novelty lies in its ability to provide personalized, real-time, and minimally invasive treatments, which are not achievable with the original patent's method.

Alternative embodiments of the platform could include the use of different types of wearable devices, such as implantable sensors or smart patches. Variations of the composition could include different ratios of collagenase and fibroblast growth factor inhibitor or the addition of other therapeutic agents. The platform could also be adapted for treating other types of fibroids or tumors.

The personalized uterine fibroid treatment platform has significant commercial potential in the medical device and pharmaceutical industries, particularly in the areas of women's health and oncology. The platform's ability to provide more effective and minimally invasive treatments could lead to increased adoption and market share, as well as potential partnerships with healthcare providers and insurance companies.